Foretinib is an oral TKI, and compared to foretinib or RT alone, the combination of foretinib with IR significantly enhanced radiosensitivity and reduced tumor burden in esophageal cancer by inhibiting phosphorylation of c-Met [137]. The gene discussed is MET; the disease is neoplasm.